Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.
Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.
复制标题
DOI：
10.1371/journal.pone.0067059
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Johansen JS
中科院分区：
文献类型：
--
作者：
Schultz NA;Christensen IJ;Werner J;Giese N;Jensen BV;Larsen O;Bjerregaard JK;Pfeiffer P;Calatayud D;Nielsen SE;Yilmaz MK;Holländer NH;Wøjdemann M;Bojesen SE;Nielsen KR;Johansen JS
我们检验了高血浆YKL-40和IL-6与胰腺癌和短总生存期相关的假设。总共研究了来自丹麦（n = 448）和德国（n = 111）的前瞻性生物标志物研究的559例胰腺癌患者。 ELISA法测定血浆YKL-40和IL-6水平，荧光免疫法测定血清CA 19.9水平。对于所有生物标志物，预测胰腺癌的比值比（OR）均显著，CA 19.9具有最高AUC（CA 19.9：OR = 2.28，95%CI 1.97至2.68，p<0.0001，AUC = 0.94; YKL-40：OR = 4.50，3.99至5.08，p<0.0001，AUC = 0.87; IL-6：OR = 3.68，3.08至4.44，p<0.0001，AUC = 0.87）。 对手术患者进行的多变量考克斯分析（YKL-40、IL-6、CA 19.9、年龄、分期、性别）显示，术前高IL-6和CA 19.9（根据正常值二分）与总生存期短独立相关（CA 19.9：HR = 2.51，1.22-5.15，p = 0.013; IL-6：HR = 2.03，1.11 - 3.70，p = 0.021）。 对不可手术患者（IIB-IV期）的多变量考克斯分析显示，每种生物标志物的治疗前高水平与总生存期短独立相关（YKL-40：HR = 1.30，1.03至1.64，p = 0.029; IL-6：HR = 1.71，1.33至2.20，p<0.0001; CA 19.9：HR = 1.54，1.06至2.24，p = 0.022）。 与两种生物标志物水平正常的患者相比，术前IL-6和CA均升高19.9的患者的总生存期较短（p<0.005）（12个月后存活率分别为45%和92%）。血浆YKL-40和IL-6的诊断影响小于CA 19.9。联合应用YKL-40、IL-6和CA 19.9预处理对胰腺癌患者的预后评估可能具有临床价值。
We tested the hypothesis that high plasma YKL-40 and IL-6 associate with pancreatic cancer and short overall survival. In all, 559 patients with pancreatic cancer from prospective biomarker studies from Denmark (n = 448) and Germany (n = 111) were studied. Plasma YKL-40 and IL-6 were determined by ELISAs and serum CA 19.9 by chemiluminescent immunometric assay. Odds ratios (ORs) for prediction of pancreatic cancer were significant for all biomarkers, with CA 19.9 having the highest AUC (CA 19.9: OR = 2.28, 95% CI 1.97 to 2.68, p<0.0001, AUC = 0.94; YKL-40: OR = 4.50, 3.99 to 5.08, p<0.0001, AUC = 0.87; IL-6: OR = 3.68, 3.08 to 4.44, p<0.0001, AUC = 0.87). Multivariate Cox analysis (YKL-40, IL-6, CA 19.9, age, stage, gender) in patients operated on showed that high preoperative IL-6 and CA 19.9 (dichotomized according to normal values) were independently associated with short overall survival (CA 19.9: HR = 2.51, 1.22–5.15, p = 0.013; IL-6: HR = 2.03, 1.11 to 3.70, p = 0.021). Multivariate Cox analysis of non-operable patients (Stage IIB-IV) showed that high pre-treatment levels of each biomarker were independently associated with short overall survival (YKL-40: HR = 1.30, 1.03 to 1.64, p = 0.029; IL-6: HR = 1.71, 1.33 to 2.20, p<0.0001; CA 19.9: HR = 1.54, 1.06 to 2.24, p = 0.022). Patients with preoperative elevation of both IL-6 and CA 19.9 had shorter overall survival (p<0.005) compared to patients with normal levels of both biomarkers (45% vs. 92% alive after 12 months). Plasma YKL-40 and IL-6 had less diagnostic impact than CA 19.9. Combination of pretreatment YKL-40, IL-6, and CA 19.9 may have clinical value to identify pancreatic cancer patients with the poorest prognosis.
登录
查看更多内容
影响因子：
5.7
作者：
Faibish M;Francescone R;Bentley B;Yan W;Shao R
通讯作者：
Shao R
影响因子：
8
作者：
Kawada, M.;Seno, H.;Kanda, K.;Nakanishi, Y.;Akitake, R.;Komekado, H.;Kawada, K.;Sakai, Y.;Mizoguchi, E.;Chiba, T.
通讯作者：
Chiba, T.
影响因子：
50.3
作者：
Hanahan, Douglas;Coussens, Lisa M.
通讯作者：
Coussens, Lisa M.
影响因子：
2.6
作者：
Knudsen, Lene S.;Christensen, I. B. J.;Johansen, Julia S.
通讯作者：
Johansen, Julia S.
影响因子：
3.2
作者：
Brochner, Christian B.;Johansen, Julia S.;Mollgard, Kjeld
通讯作者：
Mollgard, Kjeld